Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03112603 · OUTCOME

Percentage of Participants Successfully Tapered Off of All Corticosteroids

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) · Source last updated 2025-08-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
up to Day 179

What was measured

All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants who successfully tapered off of all corticosteroids. Participants who completely tapered off corticosteroids refer to those who permanently discontinued steroids as per the dose administration panel and who did not restart steroids in the same interval. Participants who were tapered off and continued follow-up were also counted as being tapered off with 0 dose in subsequent intervals until they discontinued from the main treatment period or restarted steroid treatment.

Analysis population: FAS. Only participants with available data were analyzed.

Groups in this outcome

Ruxolitinib

Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).

Best Available Therapy

Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ruxolitinib165
Best Available Therapy158

Reported measurements

Day 1 to ≤ Day 28
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib2.5Not reportedNot reportedNot reportedNot reported
Best Available Therapy2.6Not reportedNot reportedNot reportedNot reported
Day 29 to ≤ Day 56
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib9.6Not reportedNot reportedNot reportedNot reported
Best Available Therapy5.4Not reportedNot reportedNot reportedNot reported
Day 57 to ≤ Day 84
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib14.0Not reportedNot reportedNot reportedNot reported
Best Available Therapy8.5Not reportedNot reportedNot reportedNot reported
Day 85 to ≤ Day 112
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib16.3Not reportedNot reportedNot reportedNot reported
Best Available Therapy10.3Not reportedNot reportedNot reportedNot reported
Day 113 to ≤ Day 140
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib19.7Not reportedNot reportedNot reportedNot reported
Best Available Therapy12.4Not reportedNot reportedNot reportedNot reported
Day 141 to ≤ Day 168
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib24.2Not reportedNot reportedNot reportedNot reported
Best Available Therapy16.8Not reportedNot reportedNot reportedNot reported
Day 169 to ≤ Day 179
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib24.1Not reportedNot reportedNot reportedNot reported
Best Available Therapy15.9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2.5
      2. group Id
        OG001
        value
        2.6
    title
    Day 1 to ≤ Day 28
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        9.6
      2. group Id
        OG001
        value
        5.4
    title
    Day 29 to ≤ Day 56
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        14.0
      2. group Id
        OG001
        value
        8.5
    title
    Day 57 to ≤ Day 84
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        16.3
      2. group Id
        OG001
        value
        10.3
    title
    Day 85 to ≤ Day 112
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        19.7
      2. group Id
        OG001
        value
        12.4
    title
    Day 113 to ≤ Day 140
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        24.2
      2. group Id
        OG001
        value
        16.8
    title
    Day 141 to ≤ Day 168
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        24.1
      2. group Id
        OG001
        value
        15.9
    title
    Day 169 to ≤ Day 179
denoms
  1. counts
    1. group Id
      OG000
      value
      165
    2. group Id
      OG001
      value
      158
    units
    Participants
description
All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants who successfully tapered off of all corticosteroids. Participants who completely tapered off corticosteroids refer to those who permanently discontinued steroids as per the dose administration panel and who did not restart steroids in the same interval. Participants who were tapered off and continued follow-up were also counted as being tapered off with 0 dose in subsequent intervals until they discontinued from the main treatment period or restarted steroid treatment.
groups
  1. description
    Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).
    id
    OG000
    title
    Ruxolitinib
  2. description
    Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.
    id
    OG001
    title
    Best Available Therapy
param Type
NUMBER
population Description
FAS. Only participants with available data were analyzed.
reporting Status
POSTED
time Frame
up to Day 179
title
Percentage of Participants Successfully Tapered Off of All Corticosteroids
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice